Agilent Technologies acquired ACEA Biosciences for approximately $250 million, a transaction completed in November 2018, structured as all cash.
ACEA Biosciences operates in Life Sciences and Applied Markets, is based in San Diego, California, USA. ACEA Biosciences develops real-time, label-free cell-analysis platforms, including NovoCyte benchtop flow cytometers and the impedance-based xCELLigence real-time cell-analysis system, used in immuno-oncology, preclinical drug discovery and academic research.
ACEA brought together two pioneers in live-cell function and metabolism measurement and broadened Agilent's cell-analysis instrument portfolio.
Advisory firms were not disclosed for this transaction.